Vertex sets Nov. 30 PDUFA for povetacicept
Vertex Pharmaceuticals set a Nov. 30 Prescription Drug User Fee Act target date for povetacicept in IgA nephropathy, citing phase data showing a 52% UPCR drop and biomarker gains.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.